Evidence map›Paper›PMID 38562937›Full record

ArticleFrontiers in immunology2024

Diminished neutralizing activity against the XBB1.5 strain in 55.9% of individuals post 6 months COVID-19 mRNA booster vaccination: insights from a pseudovirus assay on 1,353 participants in the Fukushima vaccination community survey, Japan.

Tianchen Zhao, Yuta Tani, Chieko Makino-Okamura, Morihito Takita, Chika Yamamoto, Eiki Kawahara, Toshiki Abe, Sota Sugiura, Hiroki Yoshimura, Taiga Uchiyama and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Tianchen Zhao *General Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan.
Yuta Tani *General Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan.
Chieko Makino-Okamura *Division of Immunology, Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University, Hirakata, Osaka, Japan.
Morihito TakitaGeneral Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan.
Chika YamamotoGeneral Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan.
Eiki KawaharaDivision of Immunology, Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University, Hirakata, Osaka, Japan.
Toshiki AbeDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan.
Sota SugiuraGeneral Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan.
Hiroki YoshimuraGeneral Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan.
Taiga UchiyamaDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan.
Isato YamazakiDivision of Immunology, Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University, Hirakata, Osaka, Japan.
Harumichi IshigameDivision of Immunology, Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University, Hirakata, Osaka, Japan.
Takaharu UenoDepartment of Microbiology, Kansai Medical University, School of Medicine, Hirakata, Osaka, Japan.
Kazu OkumaDepartment of Microbiology, Kansai Medical University, School of Medicine, Hirakata, Osaka, Japan.
Masatoshi WakuiDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Hidehiro FukuyamaDivision of Immunology, Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University, Hirakata, Osaka, Japan.
Masaharu TsubokuraGeneral Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan.
Fukushima Medical University · JPKansai Medical University · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigates the neutralizing activity against the XBB1.5 variant and the ancestral strain in a population post-bivalent vaccination using a pseudo virus assay validated with authentic virus assay. While bivalent booster vaccination and past infections enhanced neutralization against the XBB 1.5 strain, individuals with comorbidities showed reduced responses. The study suggests the need for continuous vaccine updates to address emerging SARS-CoV-2 variants and highlights the importance of monitoring real-world immune responses.

Indexed as

COVID-19HumansJapanRNA, MessengerSARS-CoV-2Surveys and QuestionnairesVaccinationRNA, Messengerantibody waningbivalent vaccinationmRNA vaccination vulnerable populationSARS-CoV2vaccination

Identifiers

PMID38562937
PMCPMC10983612
OpenAlexW4392913497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.